Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CLIA transfer

This article was originally published in The Gray Sheet

Executive Summary

FDA intends to provide guidance on how requests for categorizations under the Clinical Laboratory Improvement Amendments of 1988 will be "administratively processed," the agency says in an Aug. 23 letter to in vitro diagnostic makers. The guidance will be made available prior to Jan. 31, 2000, the time at which the agency will begin handling the categorization duties currently conducted by the Centers for Disease Control and Prevention (1"The Gray Sheet" April 19, p. 3). A website also will be created to assist manufacturers with the transfer, FDA says
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT012219

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel